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miRNA-124 in immune System 
and immune Disorders
Zhen Qin†, Peng-Yuan Wang†, Ding-Feng Su* and Xia Liu*
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
In recent years, miR-124 has emerged as a critical modulator of immunity and inflam-
mation. Here, we summarize studies on the function and mechanism of miR-124 in the 
immune system and immunity-related diseases. They indicated that miR-124 exerts a 
crucial role in the development of immune system, regulation of immune responses, and 
inflammatory disorders. It is evident that miR-124 may serve as an informative diagnostic 
biomarker and therapeutic target in the future.
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iNTRODUCTiON
microRNAs (miRNAs) are a class of short non-coding single-stranded molecules with 18–25 nt, 
involved in the post-transcriptional regulation of gene expression (1, 2). miRNA biogenesis is initiated 
via transcription by RNA polymerase II as part of capped and polyadenylated primary transcripts 
(pri-miRNAs) (2). The pri-miRNAs are further processed by a complex called “Microprocessor,” 
consisting of a member of the ribonuclease III family (Drosha) and its cofactor (DGCR8), to release 
an approximately 65-nt stem-loop precursor miRNA (pre-miRNA). The resulting pre-miRNAs are 
exported by exportin-5 to the cytoplasm where hairpin precursor sequences are cleaved by the Dicer 
enzyme to generate 22-bp double-stranded miRNA duplexes. Mature miRNA in the duplexes is 
released by helicase and assembled into RNA-induced silencing complex (RISC) to recognize and 
silence the target (3–6).
miRNAs are increasingly being distinguished as crucial modulators of gene expression in many 
biological processes, such as cell maturation (7), differentiation, proliferation (8), metastasis (9), 
apoptosis (2), and autophagy (10). Specifically, miR-124 was initially verified by cloning studies 
in mice (11). There are three subtypes of miR-124, named miR-124-1, miR-124-2, and miR-124-3, 
which have distinct chromosome locations. While the precursors of miR-124 from different spe-
cies are different, the sequences of mature miR-124 in human, mice, rats are completely identical. 
Noteworthily, miR-124 is the most abundantly expressed miRNA in neuronal cells and is highly 
expressed in the immune cells and organs, including peripheral blood mononuclear cells, bone 
marrow, lymph node, and thymus (Figure 1) (11–13).
miR-124 in the RISC recognizes target mRNAs through imperfect base pairing. Its seed region, 
approximately 7-nt-long in the 5′-end, mediates its interaction with target mRNAs and determines 
the target specificity. It usually binds to the 3′-untranslated regions (3′-UTRs) of specific mRNAs 
to affect their mRNA stability or protein translation (14). Significant progresses have been made 
in assessing the biological activities and regulation of miR-124, including experimental validation 
of a number of predicted targets and the unveiling of regulatory mechanism. Thus, it is possible 
now to comprehend the roles of miR-124 in innate and specific immunity as well as immunity and 
inflammation-associated diseases.
FiGURe 1 | mRNA expression in normal human tissues for miR-124-1 
Gene (http://www.genecards.org/cgi-bin/carddisp.pl?gene=MiR124-
1&keywords=miRNA-124).
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miR-124 iN THe iNNATe AND ADAPTive 
iMMUNe CeLLS
miR-124 in Hematopoietic Cells
miRNAs have been demonstrated to regulate hematopoiesis 
through targeting different genes post-transcriptionally (15). 
Recently, miR-124 is found to be expressed in a low level in human 
cord blood CD34(+) cells, but considerably upregulated during 
culturing and differentiation of these cells. Moreover, miR-124 
decreases Tip110 expression and promotes differentiation of 
human cord blood CD34(+) cells, suggesting an important role 
of miR-124/Tip110 in hematopoiesis (16).
miR-124 in the Dendritic Cell Subsets
miR-124 is likely involved in the process of dendritic cell (DC) 
subset development. DCs include plasmacytoid DCs (pDCs) 
and classical DCs (cDCs) subpopulations, with the latter 
consisting of cDC1 and cDC2 lineages. DC subsets from the 
culture of mouse bone marrow showed high expression of 
miR-124, which is dominantly expressed in CD24(+) cDC1 
cells compared with pDCs and CD172α+cDC2 cells. miR-124 
is supposed to be involved in the processes of DC subset 
development by targeting the transcript of TCF4, a critical 
transcription factor in the development and homeostasis of 
pDCs (17).
miR-124 in the Resident Macrophage 
Polarization
Macrophages function depending on polarization status. M1 
macrophages are characterized by a proinflammatory pheno-
type, while M2 macrophages display anti-inflammatory one 
(18, 19). It has been reported that resident macrophages nest 
in various tissues including the central nervous system (CNS), 
peritoneum, lungs, liver, and adipose tissues. They express a 
number of M2 markers, such as Ym1, IL-10, IL-4, CD206, Fizz1, 
and Arg1, suggesting that tissue-resident macrophages are often 
M2 dominant under normal physiological conditions (20). 
miR-124 is essential for the induction and maintenance of the 
M2 phenotype in tissue-resident macrophages, as reflected by 
miR-124 inhibitor abrogating the upregulation of M2 markers 
(CD206, Ym1) and downregulation of M1 markers (CD86, iNOS, 
TNF) in M2-polarized macrophages (21). miR-124 serves as a 
universal regulator of M2 macrophage polarization, and C/EBP-α 
is regarded as the mediator of the miR-124 effect on macrophage 
polarization, although it remains unclear how C/EBP-α sup-
presses M2 polarization (22).
miR-124 in the CD4+ T Cell Differentiation
miR-124 is a critical mediator for the differentiation of naïve CD4+ 
T cells into T helper type 1 [T(H)1] and T(H)17 cells in vitro and 
in vivo, which is regulated by the upstream methyl CpG-binding 
protein 2 (MeCP2) protein. Loss of MeCP2 in CD4+ T cells results 
in the decreased expression of miR-124, with consequently the 
accumulation of miR-124-targeting protein suppressor of 
cytokine signaling 5 (SOCS5). SOCS5 then inhibits STAT1 and 
STAT3 activation, further represses the differentiation of T(H)1 
and T(H)17 cells, respectively (23).
miR-124 iN THe iMMUNe ReSPONSeS
miR-124 in innate immune Responses
The innate immune system coordinates host defenses through 
pattern recognition receptors, such as toll-like receptors (TLRs) 
(24). miRNAs represent a component of the innate immune 
responses that can restrain inflammatory signaling (1, 25, 26). 
It is reported that miR-124 can be induced upon Mycobacterium 
bovis bacillus Calmette–Guérin (BCG) infection in both 
RAW264.7 AM cells in  vitro and murine AMs in  vivo and is 
transcriptionally regulated by TLR signaling adaptor MyD88. 
In turn, elevated miR-124 negatively modulates TLR activity in 
RAW264.7 cells by directly targeting multiple components of 
TLR signaling cascade, including the TLR6, myeloid differentia-
tion factor 88 (MyD88), TNFR-associated factor 6 (TRAF6), 
and TNF-α (27). Moreover, our lab also found activation of 
TLR4 rapidly increased the level of miR-124 in RAW264.7 
macrophages and mice, while miR-124 directly targeted 
ubiquitin-specific proteases 2 (USP2) and 14 (USP14), two 
components of deubiquitinating enzymes, to negatively regulate 
LPS-induced production of TNF-α at the post-transcriptional 
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level (28). Opioids have universal immunosuppressive effects, 
and the mechanisms are unclear. Qiu et al. have found morphine 
inhibits the innate immunity in microglia partially through 
TLRs, and miR-124 mediates this effect. Morphine promotes 
miR-124 expression in microglia, bone marrow-derived 
macrophages through upregulating p65 expression, which can 
directly bind to promoters of miR-124 and enhance miR-124 
transcription, where miR-124 mediates morphine’s inhibition 
of the TLR signaling by directly targeting a subunit of NF-κB 
p65 and TRAF6 (29).
The cholinergic anti-inflammatory pathway is a type of 
neurophysiological regulatory mechanism to the immune 
stimulus, capable of monitoring, and feedback adjusting body 
inflammatory responses. When meeting inflammatory chal-
lenge, the vagus nerve releases acetylcholine, the principal 
neurotransmitter, to ameliorate the synthesis and release 
of inflammatory cytokines and guard against tissue damage 
through the α7 subunit-containing nicotinic acetylcholine 
receptors (α7nAChRs) in the macrophages. Our lab found 
that miR-124 is a critical mediator for the cholinergic anti-
inflammatory action. miR-124 is upregulated by cholinergic 
agonists in LPS-exposed cells and mice, and miR-124 further 
modulates TLR4-induced cytokine production by targeting 
signal transducer and activator of transcription 3 (STAT3) 
to decrease IL-6 production and TNF-α converting enzyme 
(TACE) to reduce TNF-α release (30). These results indicate 
a negative regulatory role of miR-124 in fine-tuning the TLR-
triggered inflammatory responses.
miR-124 in Adaptive immune Responses
T lymphocytes are the main executors of the adaptive immune 
responses. miR-124 is reported to exert potent anti-glioma thera-
peutic effects via a T cell-mediated antitumor immune response. 
Glioma cancer stem cells (gCSCs) produce immunosuppressive 
roles in the T-cell proliferation, and miR-124 could reverse this 
suppressive effect and decrease the generation of Foxp3+ regula-
tory T-cells (Tregs). Furthermore, treatment of T-cells with miR-
124 induces marked effector response including the upregulation 
of IL-2, IFN-γ, and TNF-α. STAT3, a key pathway mediating 
immunosuppression in the tumor microenvironment, is identi-
fied as the target of miR-124 in the regulation of T-cell functions. 
In addition, miR-124 also modulates T-helper cell differentiation. 
When miR-124 is overexpressed, IL-17A + TH17 cells and FoxP3+ 
Treg induction is inhibited, whereas IFN-γ + TH1 cells differen-
tiation is strengthened (31).
miR-124 also mediates the effect of IL-7 in the generation and 
maintenance of memory T cells and benefits survival and expan-
sion of HIV-1-latently infected memory CD4+ T lymphocytes. 
IL-7 could elevate miR-124 level, which targets and downregulates 
polypyrimidine tract-binding protein (PTB) and subsequently 
leads to the elevation of CD95 on memory CD4+ T cells. Elevated 
CD95, combined with coactivated FLICE-like inhibitory protein 
(c-FLIP) and JNK by IL-7, primes CD4+ T lymphocytes to a 
survival mode and contributes to the IL-7-mediated maintenance 
of HIV-1 reservoir (32).
Critical illness-related corticosteroid insufficiency (CIRCI) 
is defined as inadequate corticosteroid activity for the 
severity of the illness. Sepsis is often accompanied with acquired 
 glucocorticoid resistance, which complicates the therapy of 
sepsis. T-cell system is the key player in the adaptive immune 
response and is considered as one of the key players in the 
pathogenesis of CIRCI. Recent studies showed that miR-124 
mediates the glucocorticoid resistance in human T-cells. T-cells 
from sepsis patients exhibit decreased glucocorticoid receptor-α 
(mediating anti-inflammatory effects) and increased miR-124 
levels. Further studies demonstrated that glucocorticoid signifi-
cantly elevates miR-124 level, which specifically downregulates 
glucocorticoid receptor-α and limits anti-inflammatory effects 
of glucocorticoids (33).
miR-124 iN iMMUNe DiSeASeS
Many inflammatory diseases and immune disorders witness 
altered miR-124 expression. Further characterization of these 
regulatory networks triggers mechanistic studies. The involve-
ment of miR-124 in immunity-related diseases and their identi-
fied targets are discussed in detail as followed.
miR-124 in CNS immune-Related Diseases
miR-124 is one type of brain-specific miRNAs and has been 
revealed to mediate the function of immune system in the 
CNS (12, 34). miR-124 was first identified as a key regulator of 
promoting microglia, one kind of macrophages that are resident 
in the brain and spinal cord, quiescence. miR-124 expression is 
decreased in activated microglia during the course of experimen-
tal autoimmune encephalomyelitis (EAE), while overexpression 
of miR-124 could promote activated microglia into a phenotype 
resembling resting microglia and suppress EAE by deactivating 
macrophages via the C/EBP-α-PU.1 pathway (22). Spinal cord 
injury remains a difficulty to be treated due to the secondary 
inflammatory damage induced by activated microglia and/or 
macrophages. Louw et  al. found that miR-124 transfection 
decreased the activation of rat microglia. Microinjected par-
ticles of chitosan/miR-124 in the peritoneum, which will be 
transported by macrophages to the site of spinal cord injury 
72  h post injection, decrease the infiltration of macrophages 
in the injured spinal cord, and therefore ameliorate spinal cord 
injury (35). Chronic pain is often associated with microglia 
activation in the spinal cord. Willemen et  al. have found that 
persistent hyperalgesia in LysM-GRK2+/− mice is associated 
with reduced miR-124 levels in spinal cord microglia, while 
intrathecal miR-124 treatment can be used to prevent and treat 
persistent inflammatory and neuropathic pain by restoring the 
increased ratio of M1/M2 type markers in spinal cord microglia/
macrophages (36).
However, miR-124 does not always act as a repressor for 
microglia activation. Epilepsy is closely relevant to dysregulated 
inflammatory pathways. Brennan et  al. have proved that status 
epilepticus leads to suppressed miR-124 expression, while syn-
thetic miR-124 significantly augments microglia activation and 
inflammatory cytokines. Further studies have demonstrated that 
miR-124 acts as a dual regulator in epilepsy, which attenuates 
epileptogenesis via targeting NRSF while promoting epilepsy via 
exaggerating inflammation (37).
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miR-124 in Peripheral immune-Related 
Diseases
Inflammatory bowel diseases (IBDs), which refer to ulcerative 
colitis (UC) and Crohn’s disease (CD), are multifactorial diseases 
with probable genetic heterogeneity. Environmental risk factors, 
such as diet, smoking, measles, or appendectomy, may contribute 
to their pathogenesis. The mechanism of IBDs has only been 
partly understood. Recent reports indicated that miR-124 might 
be involved in their regulation. Koukos et  al. found that miR-
124 is downregulated in tissues from children with UC due to 
promoter hypermethylation, while reduced levels of miR-124 
promote inflammation and the pathogenesis of UC by increasing 
expression and activity of STAT3 in colon tissues. Interestingly, 
the same group did not observe the decrease of miR-124 in adult 
UC tissues, reflecting the mechanistic differences between adults 
and pediatric UC (38). Inversely, active CD patients were found 
to have higher level of miR-124 in colon tissues and intestinal 
epithelial cells (IECs). miR-124 can directly target AHR protein 
to modulate proinflammatory cytokine production and thereby 
promote the pathogenesis of CD (39, 40). As we know, smok-
ing plays a dual role in IBD by decreasing the risk of UC and 
increasing that of CD (41), the potential mechanisms are still 
unknown. It has been reported that nicotine is thought to be the 
most important agent responsible for the effect of smoking, and 
the dual role of miR-124 in the treatment of UC and CD may 
be responsible for this discrepancy, which needs to be further 
explored.
Rheumatoid arthritis (RA) is an autoimmune disease in 
which the body’s immune system mistakenly attacks the joints. 
It is recently reported that RA patients have higher miR-124 
promoter methylation, while healthy controls have not such a 
modification, suggesting that epigenetic dysregulation may be 
involved in the development of RA (42). Moreover, Nakamachi 
et  al. found that miR-124 level significantly decreased in RA 
synoviocytes as compared with osteoarthritis (OA) synoviocytes, 
and miR-124 could target cyclin-dependent kinase 2 (CDK2) or 
monocyte chemotactic protein 1 (MCP1), adjusting proliferation 
and the ability to produce chemokines of fibroblast-like synovial 
cells (43). Subsequently, they also found that forced expression 
of miR-124 repressed adjuvant-induced arthritis (AIA) in rats 
by suppressing RANKL and NFATc1, resulting in the decreased 
synoviocyte proliferation, leukocyte infiltration, and cartilage or 
bone destruction (44). Thus, miR-124 is a promising therapeutic 
target in human RA.
Ankylosing spondylitis (AS) is a type of arthritis that affects 
the spine, and symptoms include pain and stiffness from the neck 
down to the lower back. The spine’s bones (vertebrae) may grow 
or fuse together, resulting in a rigid spine. miR-124 is upregulated 
and ANTXR2 is downregulated in peripheral blood from AS 
patients. Further studies demonstrated that miR-124 targeted 
ANTXR2 and inhibited its expression in Jurkat cells, leading to 
the activation of JNK and inducing autophagy. miR-124-ANTXR2 
might be a therapeutic target for AS (45).
miR-124 in Tumor immunity
Many studies have demonstrated the potential application of 
miR-124 as a novel immunotherapeutic agent for tumors, and 
several targets have been identified. For example, miR-124 can 
inhibit tumor by directly targeting STAT3, a key component 
mediating immunosuppression in the tumor microenvironment. 
Bellon et  al. found miR-124 inhibited adult T-cell leukemia 
(ATL) cell proliferation in vitro and tumor growth in vivo of ATL 
mouse model by targeting STAT3-Pim1 pathway (46). Wei et al. 
reported that systemic administration of miR-124 or adoptive 
miR-124-transfected T-cell-suppressed glioma by repressing the 
STAT3 pathway (31). miR-124 can suppress the fitness of B-cell 
lymphomas by targeting MYC and BCL2, which are coexpressed 
in B-cell lymphomas and associated with the poor prognosis (47). 
Meanwhile, miR-124 also increases sensitivity of B-cell lympho-
mas to glucocorticoid treatment by targeting phosphodiesterase 
4B (PDE4B) and may act as an attractive therapeutic target in B 
cell lymphoma (48).
miR-124 can exert tumor suppressive effects in human 
liver cancers. Hepatocyte nuclear factor 4α (HNF4α) reduc-
tion contributes to liver tumorigenesis and inflammation. 
Hatziapostolou et al. reported that miR-124 is an integral part of 
the circuit and a direct downstream effector of HNF4α activity, 
targeting IL-6R, and modulating IL-6R/STAT3 pathway dur-
ing hepatocellular transformation. Systemic administration of 
miR-124 suppresses hepatocellular carcinogenesis by inducing 
tumor-specific apoptosis (49). Coincidentally, Ning et  al. have 
reported that miR-124 also participates in HNF4α–NF-κB feed-
back circuit in hepatocellular carcinoma. miR-124 is elevated 
by HNF4α transcriptionally, inhibiting RelA (p65) expression 
via interaction with RelA–3′-UTR (50). Intriguingly, an acti-
vated NF-κB-centered inflammatory loop was also detected in 
node-positive non-small cell lung carcinoma (NSCLC). NF-κB-
regulated miR-124 targets MYO10, inhibiting cell invasion and 
metastasis (51).
Particularly, miR-124 is known to be methylation silenced 
during exposure to chronic inflammation, which is correlated 
with the higher epidemiologic risk of cancer. Ueda et al. have 
reported that three miR-124 genes are methylated, whereas 
CDK6 is highly expressed in tissues from patients with colitis-
associated cancer (CAC), sporadic colorectal cancer, and dys-
plasia. During carcinogenesis in UC patients, miR-124 genes 
are methylated. The methylation level of miR-124-3 could be 
recognized as a valuable marker for estimating individual risk of 
CAC (52). Methylation of hsa-miR-124-2 was previously found 
to be indicative for cervical (pre)cancer. Methylation markers 
combined with HPV testing might offer a full molecular screen-
ing strategy to the many HIV-infected women who are also 
hrHPV-positive (53).
miR-124 in viral immunity
Several studies have revealed alterations in cellular miRNA 
profiles following HIV-1 infection, which are mostly involved 
in inhibiting viral infection. However, several miRNAs, 
including miR-124, were found to modulate viral spread in 
T-lymphocytes and HeLa-CCR5 cell lines. Following infection, 
let-7c, miR-34a, or miR-124 was upregulated, and they targeted 
and downregulated p21 and TASK1, which eventually led to 
increased virion release and higher copy number of viral 
genome transcripts in infected cells, suggesting that HIV-1 
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TABLe 1 | miR-124 in immune system and immune disorders.
Physiological and 
pathological conditions
expression Target Action Reference
Hematopoiesis differentiation Upregulation in the differentiation of 
human cord blood CD34(+) cells
Tip110 Regulate hematopoiesis differentiation (16)
DC subset development High expression in CD24(+) cDC1 
cells during the culture of mouse 
bone marrow
TCF4 Regulate DC subset development (17)
Resident macrophage 
polarization
Constitutive expression in  
macrophages
– Promote M2 polarization of resident 
macrophages
(21)
Experimental autoimmune 
encephalomyelitis (EAE)
Downregulation in activated  
microglia
C/EBP-α-PU.1 Promote microglia quiescence and protect 
against EAE
(22)
CD4+ T cell differentiation Upregulation in the process  
of CD4+ T cell differentiation
SOCS5 Stimulate naïve CD4+ T cells to differentiate into 
T helper type 1 [T(H)1] and T(H)17 cells
(23)
BCG infection Upregulation in alveolar macrophages 
upon BCG infection
TLR6, MyD88,  
TRAF6, and TNF-α
Restrain inflammatory signaling (27)
TLR4 signaling Upregulation in LPS-stimulated 
RAW264.7 macrophages and mice
USP2, USP14 Negatively regulate TNF-α production (28)
Morphine’s effect in innate 
immunity
Upregulation in microglia and 
macrophages treated by morphine
NF-κB p65 and  
TRAF6
Mediate morphine’s inhibition in the TLR signaling (29)
Cholinergic anti- 
inflammation pathway
Upregulation by cholinergic agonists STAT3 and TACE Critical mediator for the cholinergic anti-
inflammatory action
(30)
Gliomas Absence in all grades and  
pathological types of gliomas
STAT3 in T cells and 
in glioma cancer stem 
cells (gCSC)
Anti-glioma effects (31)
Corticosteroid resistance in 
sepsis
Upregulation by glucocorticoid  
in T cells
GR-α Limit anti-inflammatory effects of glucocorticoids (33)
Spinal cord injury Forced expression – Decrease microglia activation and ameliorate 
spinal cord injury
(35)
Chronic pain Downregulation in spinal cord  
microglia
– Increase the ratio of M1/M2 type markers, and 
prevent or treat chronic pain
(36)
Status epilepticus Downregulation Inhibit NRSF and 
augment microglia 
activation
Attenuate epileptogenesis via targeting NRSF 
while promote epilepsy via exaggerating 
inflammation
(37)
Ulcerative colitis (UC) Downregulation in colon tissues 
from children with UC
STAT3 Inhibit inflammation and the pathogenesis of UC (38)
Crohn’s disease (CD) Upregulation in colon tissues and 
intestinal epithelial cells
AHR Modulate proinflammatory cytokine production 
and promote the pathogenesis of CD
(40)
Rheumatoid arthritis (RA) Downregulation in RA synoviocytes CDK-2, MCP-1,  
NFATc1, and RANKL
Decrease synoviocyte proliferation, leukocyte 
infiltration and cartilage or bone destruction, and 
protect against RA
(43, 44)
Ankylosing spondylitis (AS) Upregulation in peripheral blood 
from AS patients
ANTXR2 Therapeutic action for AS (45)
Adult T-cell leukemia (ATL) Downregulation STAT3-Pim1 Inhibit ATL-cell proliferation and tumor growth of 
ATL mouse model
(46)
B-cell lymphomas (BCL) Downregulation P65 Suppress the fitness of BCL (47)
MYC
BCL2
PDE4B Increase sensitivity of BCL to glucocorticoid (48)
Liver cancers Downregulation in hepatocellular 
oncogenesis
IL-6R and P65 Tumor suppressive effects (49, 50)
Non-small cell lung carcinoma 
(NSCLC)
Downregulation in highly invasive  
sub-cell lines and node-positive  
NSCLC specimens
MYO10 Inhibit cell invasion and metastasis (51)
Colitis-associated cancer (CAC) Methylation in tissues from patients 
with CAC
CDK6 The methylation level of miR-124-3 is a promising 
marker for estimating individual risk of CAC
(52)
Cervical (pre)cancer Methylation – Indication of cervical (pre)cancer (53)
(Continued)
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could utilize the host miRNA cellular systems to produce a 
more efficient infection process via blocking the mechanism of 
innate inhibition (54). Additional studies have demonstrated 
this regulation. Through inducing miR-124, IL-7 has been 
shown to elevate CD95 in CD4(+) T cells from HIV-1-infected 
individuals and prime CD4(+) T lymphocytes to CD95-
mediated signals, leading to the IL-7-mediated maintenance 
of HIV-1 reservoir (32).
miRNA deep sequencing was performed to probe into the 
contribution of miRNAs to the host immune response to virus 
infection. Intriguingly, pathway analysis of miRNAs and targets 
has shown that increased miR-124-3p interplays with innate 
immunity-related pathways in spleen tissues of mice infected 
with A/Swine/GD/2/12 (H1N1) virus. Further master of the roles 
played by these miRNAs in influenza virus infection will acquire a 
good comprehension of host–pathogen interactions (55).
Bian et  al. found miR-124 specifically responded to the 
Enterovirus 71 (EV71) infection and interferon (IFN) treat-
ment, and they further predicted some related signaling 
pathways, which would be helpful to elucidate the interaction 
between the virus and the host (56). In addition, the expression 
of hsa miR-124-3p is significantly upregulated in the HCMV 
latent infection library (57). Japanese encephalitis virus (JEV) 
can infect neurons and directly cause lethal encephalitis. Yen 
et  al. inserted two copies of a perfectly matched miR-124 
recognition element into the 3′-UTR of viral RNA to create 
infectious JEV recombinant RP-124PT (rRP-124PT). The effect 
of rRP-124PT was attenuated in infected mice as compared 
with MRE mutant and parental strains. Immunization with 
rRP-124PT appeared to elicit full protective immunity against 
subsequent JEV lethal challenge, indicating that endogenous 
neuron-specific miR-124 could be used to restrict viral neu-
rotropism and consequently diminish the neurovirulence of 
JEV in mice (58).
CONCLUSiON AND PeRSPeCTiveS
Large numbers of studies in different cells and systems have 
found that miR-124 is a critical modulator of immune cells, 
inflammatory, and immunological responses. In many cases, 
miR-124 is induced by the inflammatory or immunological 
signals and, in turn, functions as a negative regulator for these 
signals, forming a negative feedback to help maintain homeo-
stasis. Physiological and pathological changes and their signifi-
cance of miR-124 are summarized in Table 1. Noteworthily, it 
has been demonstrated that a particular miRNA could often 
target multiple proteins, and a particular protein might be 
regulated by multiple miRNAs. Therefore, algorithm analysis 
based on miRNA profile as well as molecules in activated signal 
pathway will likely provide a more comprehensive picture for 
understanding the regulatory action of miRNA (56). Such 
analysis may also shed new insight on the roles of miR-124 in 
infectious and immunological diseases.
The alterations of miR-124 have been found in many inflamma-
tory and immunological diseases. Therefore, assessing miR-124 
in various body fluids (59–61) might be an informative biomarker 
for the timely diagnosis and prognosis of inflammatory diseases. 
Additionally, stable miR-124 mimic and inhibitor are candidates 
for therapeutics that modulate inflammatory and immunological 
diseases. Thus, further exploring the specific roles of miR-124 
under physiological and pathological conditions may likely bear 
fruitful results in the foreseeable future.
Recently, a report has aroused widespread attention that 
precursor miRNAs could compete with their mature miRNA 
counterparts. Roy-Chaudhuri et al. validated this for miR-124 and 
the SNAI2 3′-UTR. Therefore, miR-124 precursors are expected 
to serve as post-transcriptional regulators of miRNA activities 
rather than mere biogenesis midbodies (62). The regulatory role 
of miR-124 precursors in immune regulation might be a novel 
research frontier.
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Physiological and 
pathological conditions
expression Target Action Reference
HIV-1 infection Upregulation following infection p21 and TASK1 Increase viral spread in T-lymphocytes and HeLa-
CCR5 cell lines
(54)
Upregulation by IL-7 PTB Benefit survival and expansion of HIV-1-latently 
infected memory CD4+ T lymphocytes
(32)
A/Swine/GD/2/12 (H1N1) virus 
infection
Upregulation Innate immunity- 
related pathways
Pathway analysis (55)
Enterovirus 71 (EV71) infection Upregulation – Indicate virus and the host interaction (56)
HCMV latent infection Upregulation of hsa miR-124-3p – – (57)
TABLe 1 | Continued
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